CSL Behring announces new Site Head for CSL Behring Recombinant Facility AG in Lengnau/BE

CSL Behring is pleased to announce the appointment of Susanne Jecklin to the role of Vice President and Site Head, Lengnau, effective 1 February 2018.

Susanne Jecklin joined CSL Behring in Lengnau as Senior Director, Quality Management on 1 January 2016. After Uwe E. Jocham has decided to resign in June 2017 she has been leading the site for the last ten months. In that time, Susanne Jecklin has driven several projects and together with the Lengnau Leadership Team continued to develop the strategy. “Our ultimate objective is to deliver the new recombinant products to our patients helping them to live full lives. The already more than 100 employees in Lengnau are committed to developing and delivering the innovative biotherapeutic specialty products that patients want and need. I look forward to working with this magnificent team and all the people and companies involved in the Lengnau project,” says Susanne Jecklin.

Lengnau in the Canton of Bern was chosen for the planned commercial production site for the manufacture of recombinant hemophilia therapies in May 2014. The new site in Lengnau will create more than 300 new jobs and stimulate investments of approximately one billion Swiss Francs over a period of six years. The site is expected to be operational in 2020.

About CSL Behring Recombinant Facility AG (RCF)

CSL Behring RCF in Lengnau is part of CSL Behring. CSL Behring is a global biotherapeutics leader which is driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited, headquartered in Melbourne, Australia, employs nearly 20,000 people providing its life-saving, life-changing therapies to people in more than 60 countries.

In recent years, CSL Behring has closely collaborated with its parent company CSL Limited to develop a number of novel recombinant hemophilia therapies. The new plant in Lengnau will manufacture these three new therapies on a commercial scale and supply the markets worldwide. The treatment with recombinant coagulation factors will help hemophilia patients around the world to live a full life without limiting the quality of life despite their bleeding disorder. When operational in 2020, Lengnau will manufacture the company's recombinant products.